Exquando uses cookies on this website to provide you with the best possible browsing experience. If you would like more information on the use of cookies, you can consult our Cookies policy. By continuing to browse or use our site without having accepted or refused cookies, only cookies essential for browsing our website are used. You can also choose to accept all cookies or customize their use. You can change your preferences at any time via the icon cookie
Configurez les cookies / Cookies configuration / Cookies configuratie

(FR) Les cookies fonctionnels sont essentiels pour le fonctionnement du site internet et ne peuvent être désactivés. Pour améliorer votre expérience, d'autres cookies sont utilisés. Vous pouvez choisir de les désactiver. Ils restent modifiables à tout moment via cette fenêtre.

(EN) Functional cookies are essential for the operation of the website and cannot be deactivated. To improve your experience, other cookies are used. You can choose to turn them off. They can be modified at any time via this window.

(NL) Functionele cookies zijn essentieel voor de werking van de website en kunnen niet worden gedeactiveerd. Om uw ervaring te verbeteren, worden andere cookies gebruikt. U kunt ervoor kiezen om ze uit te schakelen. Ze kunnen op elk moment worden gewijzigd via dit venster.

Cookies fonctionnels / Functional cookies / Functionele cookies
Cookies d'analyse et de marketing / Analysis and marketing cookies / Analyse- en marketingcookies
En savoir plus sur la politique d'usage des cookies / Learn more about the use of cookies policy / Meer informatie over het gebruik van het cookiebeleid
Sauvegarder / Save / Sparen

Exquando enters in a three-year collaboration agreement with GSK Biologicals for its document control services

Following a call for tender for its document control services, GSK Biologicals recently announced its decision to entrust Exquando with a three-year collaboration starting on 1 April 2011. 

The agreement is for the delivery of document control and document management services for around 40 construction projects representing an investment of several hundred million Euros per year. Exquando will operate with a team of document control professionals and with the help of document operators based in Vietnam.

GSK Biologicals is part of the GlaxoSmithKline Group, the world’s second largest leading research-based pharmaceutical and healthcare group. GSK Biologicals, with its headquarters in Wavre, Belgium, is one of the world’s leading vaccine producers and employs around 6,200 people worldwide.

For its major Belgian and international engineering and construction projects, GSK Biologicals was looking to develop a long-term partnership with a reliable and professional service provider to which it could delegate its document control activities.

The strengths of Exquando offer relies in its long expertise and track record of innovation in Entreprise Content Management; its profound knowledge and understanding of GSK Biologicals, its projects and its people; its partnerships with well-established organizations; and last but not least its team of content professionals who have an in-depth understanding of the document control discipline.

 Marc Ansoult and Dara Duong, Exquando co-founders and Managing Directors, comment: “This collaboration is a major milestone for Exquando as it consolidates our ongoing working relationship with GSK Biologicals and enables us to continue bringing our know-how, enthusiasm and professionalism for the benefit of our client and its partners.”

LinkedIn Facebook